Table 1. Demographics and Clinical Characteristics of Study Participants.
| Overall n = 107 | RRMS n = 71 | Progressive MS n = 36 | p | |
|---|---|---|---|---|
| Baseline demographic and clinical characteristics | ||||
| Age, yr; mean (SD) | 44.2 (12.1) | 38.9 (10.3) | 54.6 (8.2) | <0.01a |
| Female; n (%) | 75 (70.1) | 51 (71.8) | 24 (66.7) | 0.58b |
| Disease duration, yr; median (Q1–3) | 10 (4–16) | 7 (3–11) | 16 (11–24) | <0.01a |
| EDSS; median (Q1–3)d | 3 (2–6) | 2 (1.5–3.0) | 6 (5.5–6.5) | <0.01a |
| Disease-modifying therapy; n (%) | <0.01c | |||
| • Interferon beta 1a | 25 (23) | 20 (28) | 5 (14) | |
| • Interferon beta 1b | 7 (7) | 4 (6) | 3 (8) | |
| • Glatiramer acetate | 29 (27) | 21 (30) | 8 (22) | |
| • Natalizumab | 24 (22) | 23 (32) | 1 (3) | |
| • None | 22 (21) | 3 (4) | 19 (53) | |
| Clinical and radiological characteristics during follow-up | ||||
| Follow-up duration, mo; median (mean; SD; range) | ||||
| • OCT | 46.2 (41.4; 14.0; 7–60) | 46.2 (41.2; 14.5; 7–60) | 45.5 (41.7; 12.9; 12–58) | 0.99a |
| • MRI | 38.7 (36.6; 16.3; 11–63) | 37.8 (35.4; 16.9; 11–62) | 43.5 (39.0; 15.0; 11–63) | 0.40a |
| Nonocular relapses; n (%) | 24 (22.4) | 23 (32.4) | 1 (2.8) | <0.01c |
| New gadolinium-enhancing lesions; n (%) | 29 (27.1) | 24 (33.8) | 5 (13.9) | 0.03b |
| New T2 lesions; n (%) | 42 (39.3) | 36 (50.7) | 6 (16.7) | <0.01b |
a
Wilcoxon rank-sum test.
b
Chi-square test.
c
Fisher's exact test.
d
Available for 66 RRMS and 34 PMS patients.
AON = acute optic neuritis; EDSS = expanded disability status scale; OCT = optical coherence tomography; MRI = magnetic resonance imaging; RRMS = relapsing-remitting multiple sclerosis; SD = standard deviation; Q1 = first quartile; Q3 = third quartile.